Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial-Reference-Cited by-同舟云学术

Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial

Published:2024-06 Issue: Volume:72 Page:102624
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Hansen Morten S.^ORCID,Wölfel Eva M.,Jeromdesella Shakespeare,Møller Jens-Jakob K.,Ejersted Charlotte,Jørgensen Niklas R.,Eastell Richard,Hansen Stinus G.,Frost Morten

Funder

Region of Southern Denmark

Gangstedfonden

Novo Nordisk

Novo Nordisk Foundation

Publisher

Elsevier BV

Reference30 articles.

1. Thinking inside and outside the envelopes of bone: dedicated to PDD;Szulc;Osteoporos Int,2009

2. Epidemiology of fracture risk with advancing age;Ensrud;J Gerontol A Biol Sci Med Sci,2013

3. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update;Shoback;J Clin Endocrinol Metab,2020

4. Adverse effects of media reports on the treatment of osteoporosis;Cipriani;J Endocrinol Invest,2018

5. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019;Collaborators;Lancet Healthy Longev,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug;Arthritis Research & Therapy;2024-07-12

2. Bone health in adults with obesity before and after interventions to promote weight loss;The Lancet Diabetes & Endocrinology;2024-07